Compare First Solar, Inc. (FSLR) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Gilead Sciences, Inc. — how do they compare? First Solar, Inc. trades at $226.6 (market cap $25.89B), while Gilead Sciences, Inc. trades at $135.91 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 6.5× First Solar, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals.
| FSLR | GILD | |
|---|---|---|
Market Cap | $25.89B | $168.35B |
Sector | Technology | Health |
52-Week High | $318.30 | $155.80 |
52-Week Low | $180.05 | $110.56 |
Enterprise Value | $24.36B | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $227.36, down 5.0% on the day, as the stock faces headwinds from multiple class action lawsuits alleging securities fraud during the February 2025-2026 period. Despite the legal overhang, the company maintains strong fundamentals with revenue growing from $2.6B in 2022 to $5.2B in 2025 and net income reaching $1.53B. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $230 and resistance at $245. Recent analyst upgrades provide optimism, with Baird raising its price target to $318 on August 11, 2026.
The investment outlook remains cautiously optimistic given FSLR's robust profitability metrics (32.5% net margin, 18.5% ROE) and analyst consensus price target of $282 representing 24% upside potential. However, significant legal risks from ongoing securities litigation and potential regulatory headwinds from solar trade policies create near-term uncertainty. Long-term growth prospects in renewable energy remain intact, but investors should weigh legal resolution timelines against fundamental strength.
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
